| 化疗联合CIK细胞回输治疗转移性肾细胞癌Ⅱ期临床研究 |
| |
| 引用本文： | 袁香庆,崔传亮,斯璐,盛锡楠,廉红云,迟志宏,郭军.化疗联合CIK细胞回输治疗转移性肾细胞癌Ⅱ期临床研究[J].肿瘤学杂志,2008,14(5):362-365. |
| |
| 作者姓名： | 袁香庆 崔传亮 斯璐 盛锡楠 廉红云 迟志宏 郭军 |
| |
| 作者单位： | 北京大学临床肿瘤学院,北京肿瘤医院北京市肿瘤防治研究所,北京,100036 |
| |
| 摘 要： | 目的]探讨化疗联合CIK细胞回输治疗转移性肾癌的疗效。方法]40例mRCC患者，采用GEM＋5-Fu化疗，化疗结束后分次回输CIK细胞，同时给予IL-2和IFN-α所有患者均接受至少2个周期治疗。结果]40例患者中4例PR（10．0％），22例SD（55．0％），14例PD（35．0％），无进展生存时间（PFS）为87d。Ⅲ-Ⅳ度毒副反应占27．5％。结论]化疗联合自体CIK细胞回输对mRCC患者有效，并延长PFS，是一种可接受的治疗模式。
|
| 关 键 词： | CIK细胞 肾肿瘤 药物疗法 |
| 文章编号： | 1671-170X(2008)05-0362-04 |
| 修稿时间： | 2007年12月28 |
Phase Ⅱ Clinical Trial of Chemotherapy Combined with Autologous CIK Cells Transfusion in the Treatment for Metastatic Renal Cell Carcinoma |
| |
| Affiliation: | YUAN Xiang-qing, CUI Chuan-liang, SI Lu, et al. (Peking University School of Oncology, Beijing Cancer Hospital, Beijing 100036, China) |
| |
| Abstract: | Purpose] To investigate the clinical effect of chemotherapy combined with autologous cytokine-induced killer （CIK） cells transfusion in the treatment for metastatic renal cell carcinoma （mRCC）. Methods] Fifty-six cases with mRCC were enrolled and underwent chemotherapy with 5-Fu and Gemcitabine followed by transfusion of CIK, IL-2 and IFN-α treatment. All patients received at least two cycles therapy. Results ] Of the 40 cases, 4 were PR （10.0%）; 22 （55.0%）, SD; 14 （35.0%）, PD. Progression free survival （PFS） was 87d; Ⅲ-Ⅳdegree toxicity accounted for 27.5%. Conclusions] Patients with mRCC can benefit from the combination of chemotherapy and autologous CIK transfusion, The treatment can prolong the peroid of PFS, and is a acceptable treatment modality. |
| |
| Keywords: | CIK eells renal neoplasms drug therapy |
| 本文献已被 维普 万方数据 等数据库收录！ |
|
